Upadacitinib (Rinvoq) is an oral Janus kinase (JAK) inhibitor indicated for the treatment of various autoimmune diseases.
What Are the Indications of Upadacitinib (Rinvoq)?
Rheumatoid Arthritis
It is indicated for adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers.
Psoriatic Arthritis
It is indicated for adult and pediatric patients aged 2 years and older with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers.
Atopic Dermatitis
It is indicated for patients aged 12 years and older, weighing at least 40 kg, with refractory moderate-to-severe atopic dermatitis whose disease is not adequately controlled by other systemic medications (including biologics) or for whom these medications are not suitable.
Ulcerative Colitis
It is indicated for adult patients with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more TNF blockers.
If TNF blockers are not suitable, patients should have received at least one approved systemic therapy before using upadacitinib.
Crohn's Disease
It is indicated for adult patients with moderately to severely active Crohn's disease who have had an inadequate response or intolerance to one or more TNF blockers.
If TNF blockers are not suitable, patients should have received at least one approved systemic therapy before using upadacitinib.
Ankylosing Spondylitis
It is indicated for adult patients with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers.
Non-Radiographic Axial Spondyloarthritis
It is indicated for adult patients with active non-radiographic axial spondyloarthritis who have had an inadequate response or intolerance to TNF blocker therapy and have objective signs of inflammation.
Polyarticular Juvenile Idiopathic Arthritis
It is indicated for pediatric patients aged 2 years and older with active polyarticular juvenile idiopathic arthritis who have had an inadequate response or intolerance to one or more TNF blockers.
Specifications and Characteristics of Upadacitinib (Rinvoq)
Extended-Release Tablets
Specifications: There are three specifications: 15 mg, 30 mg, and 45 mg.
Characteristics
The 15 mg tablet is a purple biconvex oval, measuring 14 mm × 8 mm, with "a15" engraved on one side.
The 30 mg tablet is a red biconvex oval, measuring 14 mm × 8 mm, with "a30" engraved on one side.
The 45 mg tablet is a yellow to mottled yellow biconvex oval, measuring 14 mm × 8 mm, with "a45" engraved on one side.
Oral Solution (Rinvoq LQ)
Specifications: Concentration is 1 mg/mL, with a volume of 180 mL per bottle.
Characteristics: It is a clear, colorless to pale yellow solution, accompanied by a dedicated press-fit bottle adapter and an oral dosing syringe.
Storage Methods for Upadacitinib (Rinvoq)
Extended-Release Tablets
The storage temperature should be controlled between 2°C and 25°C (36°F and 77°F).
They should always be kept in the original bottle to protect from moisture.
Do not split, crush, or chew the tablets; they must be swallowed whole.
Oral Solution (Rinvoq LQ)
The storage temperature should be between 2°C and 30°C (36°F and 86°F).
After opening, it should be used up within 60 days; any unused portion should be discarded.
Tightly close the bottle cap after each use, store the bottle upright in the original packaging, and place it in a cool, dry place.
After use, disassemble the oral dosing syringe, rinse it with clean water, and let it air dry. Do not clean it with soap or a dishwasher.
